Novartis' Ultibro Breezhaler significantly improved COPD patients' lung function after direct switch from Seretide

29 Nov 2017

Study provides further evidence that it is possible to reduce the burden of long-term inhaled steroids in many COPD patients.

Novartis has announced positive results from the FLASH study examining the safety and efficacy of directly switching chronic obstructive pulmonary disease (COPD) patients from Seretide (salmeterol/fluticasone) 50/500 mcg to Ultibro Breezhaler (indacaterol/glycopyrronium) 110/50 mcg. The study met the primary endpoint demonstrating that switching patients to Ultibro Breezhaler resulted in significantly improved lung function (trough FEV1).

Novartis' Ultibro Breezhaler significantly improved COPD patients' lung function after direct switch from Seretide

The superiority of once-daily Ultibro Breezhaler over twice-daily salmeterol/fluticasone in improving lung function and reducing the rate of COPD exacerbations has been established in previous studies. The FLASH study is the first randomized controlled trial to confirm the benefits of directly switching patients from this steroid-containing therapy to the dual bronchodilator, therefore avoiding the side effects of the long-term use of inhaled corticosteroids. Importantly, patients were switched without a wash-out period to mimic clinical practice.

"It has already been established that Ultibro Breezhaler improves patients' lung function when directly compared to Seretide in clinical trials," said Shreeram Aradhye, Chief Medical Officer and Global Head of Medical Affairs for Novartis Pharmaceuticals. "This new research is important because it shows that this benefit also exists when directly switching patients from Seretide to Ultibro Breezhaler as would happen in everyday clinical practice. The FLASH study provides further evidence that it is possible to reduce the burden of long-term inhaled steroids in many COPD patients, as recommended by global treatment guidelines".

These results further reinforce the latest GOLD recommendations, which support the use of dual bronchodilation for the majority of symptomatic COPD patients and limit the use of steroid-containing therapies to specific patient types.

Importantly, the data also indicated that the safety and tolerability profiles of the two treatments were similar.

The FLASH study results were presented at the Asian Pacific Society of Respirology (APSR) Congress in Sydney, Australia (23-26 November 2017).

Read More

Related tags

Research & Development

Related news

Plasticell wins military contract to develop regenerative medicines for the battlefield

Plasticell wins military contract to develop regenerative medicines for the battlefield

4 Sep 2018

Company to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.

Read more 
New biopharmaceutical testing laboratory to open in Geneva

New biopharmaceutical testing laboratory to open in Geneva

28 Aug 2018

SGS's expansion will enable the service provider to offer a full ICH Q6B physico-chemical characterization of biological products.

Read more 
Exosome isolation manufacturing and characterization

Exosome isolation manufacturing and characterization

13 Aug 2018

New service to reliably and reproducibly isolate exosomes from almost any biofluid.

Read more 
Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

8 Aug 2018

Company moves away from manual processing in favour of automated, scalable platforms.

Read more 
A new era for migraine patients

A new era for migraine patients

6 Aug 2018

EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

Read more 
WuXi STA and Antengene sign development and manufacturing agreement

WuXi STA and Antengene sign development and manufacturing agreement

24 Jul 2018

WuXi STA chosen for its end-to-end CMC platform for new drug development.

Read more 
ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project

ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project

18 Jul 2018

Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline.

Read more 
New screening company exploits the latest advances in microfluidics and 3D culture

New screening company exploits the latest advances in microfluidics and 3D culture

19 Jul 2018

The ability to micro size drug-cell interactions will allow pharmaceutical and biotech companies to do 100x more testing for the same money spent as well as increasing productivity.

Read more 
Natural lipid acts as potent anti-inflammatory

Natural lipid acts as potent anti-inflammatory

10 Jul 2018

Scientists see therapeutic potential against bacteria, viruses.

Read more 
Plasticell leads gene therapy manufacturing consortium

Plasticell leads gene therapy manufacturing consortium

3 Jul 2018

Consortium to develop advanced technologies for the manufacturing of ex vivo gene therapies.

Read more